Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study.
Adv Hematol
; 2022: 5581772, 2022.
Article
en En
| MEDLINE
| ID: mdl-35126524
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Adv Hematol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Italia